Studies prove antigens created by Fusion Antibodies accurately identify SARS-CoV-2
Posted onFusion Antibodies have leveraged their antigen expertise to create multiple antigens to be used against the COVID-19 pandemic.
News
Dr McGirr named ‘Future Innovator’ Winner at KTP Best of the Best Awards
Posted onDr Leona McGirr of Fusion Antibodies has received a top honour at the annual celebration of the most outstanding Knowledge Transfer Partnership (KTP) Projects.
Starting your journey into manufacturing – choosing a cell line development provider
Posted onOne of the biggest decisions which any company developing biological medicines makes is to move forward to the manufacture of their product.
Fusion Antibodies collaborates with QUB Led Project in Multi-Million Pound Funding Bid
Posted onA Belfast-based bid led by Queens University Belfast (QUB), is the only bid from Northern Ireland to be selected for the next stage of the UK Research and Innovation’s Strength in Places Fund (SIPF).
Therapeutic antibodies: the scale of the manufacturing challenge
Posted onThe most effective medicines in the world are of limited value if they can’t be produced in bulk, and at a reasonable cost. Therapeutic antibodies take years to develop. Without good oversight, each stage of development risks operating in a vacuum, with teams concentrating solely on their task before passing the candidate antibody onto the next team.
Fusion Antibodies make key Covid-19 Reagents available
Posted onAs part of our efforts to combat the Covid-19 pandemic, We have designed and expressed a panel of unique recombinant protein antigens to assist in the search for a neutralising therapeutic antibody against SARS-CoV 2.